systhiperСистемные гипертензииSystemic Hypertension2075-082X2542-2189LLC «ИнтерМедсервис»10.26442/2075082X.2018.4.180116systhiper-559Research ArticleСТАТЬИARTICLESКонцепция «полипилл» в современной кардиологииPolypill" conception in modern cardiologyЧазоваИ. Е.ChazovaI. E.c34h@yandex.ruАксеноваА. В.AksenovaA. V.aksenovaannav@gmail.comЖернаковаЮ. В.ZhernakovaYu. V.juli001@mail.ruФГБУ «Национальный медицинский исследовательский центр кардиологии» Минздрава РоссииРоссияNational Medical Research Center for Cardiology of the Ministry of Health of the Russian FederationRussian Federation20182312202215467Copyright © Чазова И.Е., Аксенова А.В., Жернакова Ю.В., 20222022Чазова И.Е., Аксенова А.В., Жернакова Ю.В.Chazova I.E., Aksenova A.V., Zhernakova Y.V.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.syst-hypertension.ru/jour/article/view/559

Объединение препаратов с антигипертензивным, гиполипидемическим, гипогликемическим и антиагрегантным действием в одну таблетку существенно повышает приверженность лечению и обеспечивает множественный контроль факторов риска, снижая риск развития сердечно-сосудистых заболеваний и фатальных событий. При этом в настоящее время еще не получены убедительные доказательства, что использование полипилла в кардиологии приводит к большему снижению частоты развития первичных конечных точек (общая смертность, фатальный инфаркт миокарда, острое нарушение мозгового кровообращения и т.д.), чем стандартная стратегия лечения. К

Combining treatments with antihypertensive, lipid lowering, antidiabetic and antiplatelet effects into a single pill significantly increases adherence to treatment, provides multiple control of risk factors and reduces the risk of cardiovascular diseases and fatal events. At the same time, there is still no convincing evidence that the using polypill in cardiology instead of the standard treatment strategy leads to a greater reduction in the incidence of primary end points (total mortality, fatal myocardial infarction, stroke, etc.)

полипиллантигипертензивная терапиясердечно-сосудистый рискpolypillantihypertensive treatmentcardiovascular riskReferencesSimpson S.H, Eurich D.T, Majumdar S.R et al. A meta-analysis of the ssociation between adherence to drug therapy and mortality. BMJ 2006; 333: 315.Simpson S.H, Eurich D.T, Majumdar S.R et al. A meta-analysis of the ssociation between adherence to drug therapy and mortality. BMJ 2006; 333: 315.Corrao G, Rea F, Ghirardi A et al. Adherence with antihypertensive drug therapy and the risk of heart failure in clinical practice. Hypertension 2015; 66: 742-9.Corrao G, Rea F, Ghirardi A et al. Adherence with antihypertensive drug therapy and the risk of heart failure in clinical practice. Hypertension 2015; 66: 742-9.Chowdhury R, Khan H, Heydon E et al. Adherence to cardiovascular therapy: a meta-analysis of prevalence and clinical consequences. Eur Heart J 2013; 34: 2940-8.Chowdhury R, Khan H, Heydon E et al. Adherence to cardiovascular therapy: a meta-analysis of prevalence and clinical consequences. Eur Heart J 2013; 34: 2940-8.Claxton A.J, Cramer J, Pierce C. A systematic review of the associations between dose regimens and medication compliance. Clin Ther 2001; 23: 1296-310.Claxton A.J, Cramer J, Pierce C. A systematic review of the associations between dose regimens and medication compliance. Clin Ther 2001; 23: 1296-310.Mancia G, Facchetti R, Bombelli M et al. Relationship of office, home,and ambulatory blood pressure to blood glucose and lipid variables in the PAMELA population. Hypertension 2005; 45: 1072-7.Mancia G, Facchetti R, Bombelli M et al. Relationship of office, home,and ambulatory blood pressure to blood glucose and lipid variables in the PAMELA population. Hypertension 2005; 45: 1072-7.Bhatt D.L, Steg P.G, Ohman E.M et al. REACH Registry Investigators. International prevalence, recognition, and treatment of cardiovascular risk factors in outpatients with atherothrombosis. JAMA 2006; 295: 180-9.Bhatt D.L, Steg P.G, Ohman E.M et al. REACH Registry Investigators. International prevalence, recognition, and treatment of cardiovascular risk factors in outpatients with atherothrombosis. JAMA 2006; 295: 180-9.Hameed M.A, Dasgupta I, Gill P. Poor adherence to antihypertensive drugs. BMJ 2016; 354: i3268.Hameed M.A, Dasgupta I, Gill P. Poor adherence to antihypertensive drugs. BMJ 2016; 354: i3268.Ambrosioni E, Leonetti G, Pessina A.C et al. Patterns of hypertension management in Italy: results of a pharmacoepidemiological survey on antihypertensive therapy. Scientific Committee of the Italian Pharmacoepidemiological Survey on Antihypertensive Therapy. J Hypertens 2000; 18: 1691-9.Ambrosioni E, Leonetti G, Pessina A.C et al. Patterns of hypertension management in Italy: results of a pharmacoepidemiological survey on antihypertensive therapy. Scientific Committee of the Italian Pharmacoepidemiological Survey on Antihypertensive Therapy. J Hypertens 2000; 18: 1691-9.Gupta A.K, Arshad S, Poulter N.R. Compliance, safety, and effectiveness of fixed-dose combinations of antihypertensive agents: a metaanalysis. Hypertension 2010; 55: 399-407.Gupta A.K, Arshad S, Poulter N.R. Compliance, safety, and effectiveness of fixed-dose combinations of antihypertensive agents: a metaanalysis. Hypertension 2010; 55: 399-407.Yusuf S, Pais P, Sigamani A et al. Comparison of risk actor reduction and tolerability of a full-dose polypill (with potassium) versus low-dose polypill (Polycap) in individuals at high risk of cardiovascular diseases the Second Indian Polycap Study (TIPS-2) investigators. Circ Cardiovasc Qual Outcomes 2012; 5: 463-71.Yusuf S, Pais P, Sigamani A et al. Comparison of risk actor reduction and tolerability of a full-dose polypill (with potassium) versus low-dose polypill (Polycap) in individuals at high risk of cardiovascular diseases the Second Indian Polycap Study (TIPS-2) investigators. Circ Cardiovasc Qual Outcomes 2012; 5: 463-71.Sanz G, Fuster V. Fixed-dose combination therapy and secondary cardiovascular prevention: rationale, selection of drugs and target population. Nat Clin Prac Cardiovasc Med 2009; 6: 101-10.Sanz G, Fuster V. Fixed-dose combination therapy and secondary cardiovascular prevention: rationale, selection of drugs and target population. Nat Clin Prac Cardiovasc Med 2009; 6: 101-10.Thom S, Poulter N, Field J et al. Effects of a fixed-dose combination strategy on adherence and risk factors in patients with or at high risk of CVD: the UMPIRE randomized clinical trial. JAMA 2013; 310: 918-29.Thom S, Poulter N, Field J et al. Effects of a fixed-dose combination strategy on adherence and risk factors in patients with or at high risk of CVD: the UMPIRE randomized clinical trial. JAMA 2013; 310: 918-29.Selak V, Elley C.R, Bullen C et al. Effect of fixed dose combination treatment on adherence and risk factor control among patients at high risk of cardiovascular disease: randomised controlled trial in primary care. BMJ 2014; 348: g3318.Selak V, Elley C.R, Bullen C et al. Effect of fixed dose combination treatment on adherence and risk factor control among patients at high risk of cardiovascular disease: randomised controlled trial in primary care. BMJ 2014; 348: g3318.Patel A, Cass A, Peiris D et al. A pragmatic randomized trial of a polypill-based strategy to improve use of indicated preventive treatments in people at high cardiovascular disease risk. Eur J Prev Cardiol 2015; 22: 920-30.Patel A, Cass A, Peiris D et al. A pragmatic randomized trial of a polypill-based strategy to improve use of indicated preventive treatments in people at high cardiovascular disease risk. Eur J Prev Cardiol 2015; 22: 920-30.Prevention of Cardiovascular Disease in Middle-aged and Elderly Iranians Using a Single PolyPill (PolyIran). http://clinical trials.gov/ct2/show/NCT01271985Prevention of Cardiovascular Disease in Middle-aged and Elderly Iranians Using a Single PolyPill (PolyIran). http://clinical trials.gov/ct2/show/NCT01271985Castellano J.M, Bueno H, Fuster V. The cardiovascular polypill: clinical data and ongoing studies. Internat J Cardiol 2015; 201 (S1): S8-S14.Castellano J.M, Bueno H, Fuster V. The cardiovascular polypill: clinical data and ongoing studies. Internat J Cardiol 2015; 201 (S1): S8-S14.Emdin C.A, Rahimi K, Neal B et al. Blood pressure lowering in type 2 diabetes: a systematic review and metaanalysis. JAMA 2015; 313: 603-15.Emdin C.A, Rahimi K, Neal B et al. Blood pressure lowering in type 2 diabetes: a systematic review and metaanalysis. JAMA 2015; 313: 603-15.Baigent C, Blackwell L, Collins R et al. Antithrombotic Trialists’ (ATT) Collaboration. Aspirin in the primary and secondary prevention of vascular disease: collaborative metaanalysis of individual participant data from randomised trials. Lancet 2009; 373: 1849-60.Baigent C, Blackwell L, Collins R et al. Antithrombotic Trialists’ (ATT) Collaboration. Aspirin in the primary and secondary prevention of vascular disease: collaborative metaanalysis of individual participant data from randomised trials. Lancet 2009; 373: 1849-60.

The authors declare that there are no conflicts of interest present.